Can synthetic blood substitute for the real thing? University of Colorado Anschutz researchers are studying it.
The blood that’s in your body right now is an extraordinary fluid — capable of flowing elegantly through as many as 60,000 miles of arteries, veins and capillaries, all while clotting to seal an opening like a nightclub bouncer and delivering oxygen molecules like a tireless UPS driver.
But when that blood is outside your body, it is preciously fragile.
Donated blood — the kind vital to all sorts of emergency and surgical care — is continually in short supply. This summer, the American Red Cross declared a national blood crisis for only the second time in its history, while, locally, blood provider Vitalant said it was facing a shortage of the versatile Type O blood.
Even when there is enough, it doesn’t last for long. Some components of donated blood can be stored only for a few days before they go bad.
But what if you could make a substitute?
Creating synthetic blood that can stand in for the real thing is one of the Holy Grails of medical science, and now the quest may be nearing an end thanks to a major new research project at the University of Colorado Anschutz.
This fall, the campus received the largest federal research grant in its history — up to $120 million over three years, from an arm of the U.S. Department of Defense — to test various synthetic blood products and tools to improve their use.
The products range from freeze-dried plasma to synthetic platelets — the things that make blood clot — to synthetic hemoglobin-type proteins that can pick up and drop off oxygen molecules where they are needed. If all goes well, researchers hope to begin early clinical trials in humans within a year and, by the end of the third year, have a suite of fully tested products ready to use widely, along with new diagnostic tools and delivery systems.
“It’s going to be hard,” said Dr. Vik Bebarta, an emergency physician who is the chair of CU Emergency Medicine. “But that’s what we like.”
Dodging funding cuts
The grant highlights a tumultuous few years for research funding at Colorado’s premier academic medical campus. CU-Anschutz is the state’s largest recipient of federal health research funding. As recently as 20 months ago, proposed cuts by the administration of President Donald Trump threatened to reduce that funding by tens of millions of dollars annually, leading to concern about the sustainability of some research projects.

But judges’ orders and congressional action have largely prevented those cuts from taking effect, meaning federal research funding at CU-Anschutz has remained stable year-to-year. Last fiscal year, for instance, CU-Anschutz says its researchers received $392 million from the National Institutes of Health, which is slightly above previous years.
Grants from other federal sources as well as from private donors, also continue to roll in, building increasingly robust research centers on the campus.

The blood-testing program, known at the Defense Department as RAPIID, will be led by CU-Anschutz’s Combat Medicine Research Center, which was founded in 2019 with Bebarta, an Air Force veteran, as director. The center focuses on medical challenges faced by the military. That includes how to deliver quicker, better care on the battlefield and also how to improve physical and mental healthcare for military members back home.
The center now counts more than 100 affiliated researchers and recently signed a deal with the U.S. Army for a first-of-its-kind medical training partnership.
Bebarta hopes the center’s benefits will spread to the broader population, as well.
“For every military injury, there’s a civilian mirror,” he said. “For every life we save on the battlefield, we can save a life on Colorado highways.”
And that brings us back to blood.
The promise of synthetic blood
Think about all the places where someone might suffer a traumatic injury that could cause a huge loss of blood. Maybe in a traffic crash or a farm accident or, perhaps, on the battlefield.
Now think about who the first medical responder would be. It might be an ambulance crew or a rural clinic or a combat medic.
None of those are set up to keep large amounts of donated blood on hand — and that’s because of how difficult storing blood can be. It needs to be refrigerated or frozen, depending on the product. It can expire really fast. Red blood cells last only 42 days in the fridge, and, while plasma can last a year in the freezer, platelets go bad after five days, according to the American Red Cross.

Even for a large hospital, storing blood can be a problem, trying to balance the incoming supply from donors with the outgoing needs. Some surgeries, for instance, may require dozens of units of blood.
“This is a huge challenge, and can cause major adverse outcomes for many patients because they don’t have access to these blood products because of limited supply and the logistics,” said Dr. Adit Ginde, an emergency physician and researcher at CU-Anschutz who will conduct clinical trials as part of the new project.
This is what makes the idea of synthetic blood so appealing. Ideally, the products would be shelf-stable and long-lasting, capable of being stored without much fuss and used effectively by the body before being cleared.

The Colorado researchers won’t be developing the products — many of which are already under development by various companies. CU-Anschutz’s job is to test those products, first in lab and animal studies before moving into humans.
Ginde said researchers, working with UCHealth University of Colorado Hospital, will start with small tests in healthy volunteers. They will then progress into trials for patients undergoing treatments where they need blood transfusions and will be able to give consent to participating in the study ahead of time. All clinical trials will be subject to approval by CU-Anschutz’s review board and other oversight bodies.
At the same time, researchers at CU-Anschutz will also be testing out new diagnostic tools aiming to help doctors make faster decisions about when a patient needs a blood product and what kind.
Ginde called the rapid three-year timeline for the project “robust,” but that’s also the point.
The grant to fund the research comes through the Defense Department’s Defense Advanced Research Projects Agency, or DARPA, which is known for moving fast on big problems and big innovations. (Among its many previous initiatives was the development of Arpanet, the early internet.)
Bebarta said the timeline reflects how urgently needed these synthetic blood products are, both for the military and in the community.
“The real hope,” he said, “is that every trauma center, every community hospital, every surgery center benefits from this.”
“We can do it,” he added, “and we will.”
Type of Story: News
Based on facts, either observed and verified directly by the reporter, or reported and verified from knowledgeable sources.
Ver nota original ↗
¿Querés un resumen rápido de esta noticia, hecho por nuestra IA?
